Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease.

Caglayan E, Huntgeburth M, Karasch T, Weihrauch J, Hunzelmann N, Krieg T, Erdmann E, Rosenkranz S.

Arch Intern Med. 2006 Jan 23;166(2):231-3.

PMID:
16432094
2.

Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication.

De LaVega AJ, Derk CT.

Expert Opin Investig Drugs. 2009 Jan;18(1):23-9. doi: 10.1517/13543780802525100 . Review.

PMID:
19053879
3.

The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon.

Friedman EA, Harris PA, Wood AJ, Stein CM, Kurnik D.

Clin Pharmacol Ther. 2007 Apr;81(4):503-9. Epub 2007 Feb 14.

PMID:
17301734
4.

Phosphodiesterase inhibitors in Raynaud's phenomenon.

Levien TL.

Ann Pharmacother. 2006 Jul-Aug;40(7-8):1388-93. Epub 2006 Jul 11. Review.

PMID:
16835313
6.

Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial.

Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N.

J Card Fail. 2008 Apr;14(3):189-97. doi: 10.1016/j.cardfail.2007.11.006.

PMID:
18381181
7.
8.

Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.

Fries R, Shariat K, von Wilmowsky H, Böhm M.

Circulation. 2005 Nov 8;112(19):2980-5.

9.
11.

Assessment of abnormal blood flow and efficacy of treatment in patients with systemic sclerosis using a newly developed microwireless laser Doppler flowmeter and arm-raising test.

Kido M, Takeuchi S, Hayashida S, Urabe K, Sawada R, Furue M.

Br J Dermatol. 2007 Oct;157(4):690-7. Epub 2007 Jul 19.

PMID:
17640308
12.

[Laser Doppler flowmetry. Principles and clinical applications in vascular acro-syndromes].

Binaghi F, Cannas F, Pitzus F.

Minerva Med. 1988 Oct;79(10):831-8. Italian.

PMID:
3185948
13.

The microcirculatory effects of peripheral sympathectomy.

Koman LA, Smith BP, Pollock FE Jr, Smith TL, Pollock D, Russell GB.

J Hand Surg Am. 1995 Sep;20(5):709-17.

PMID:
8522734
14.

Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.

Ravipati G, McClung JA, Aronow WS, Peterson SJ, Frishman WH.

Cardiol Rev. 2007 Mar-Apr;15(2):76-86. Review.

PMID:
17303994
15.

Effects of vardenafil, a phosphodiesterase type-5 inhibitor, on sphincter of Oddi motility in patients with suspected biliary sphincter of Oddi dysfunction.

Cheon YK, Cho YD, Moon JH, Im HH, Jung Y, Lee JS, Lee MS, Shim CS.

Gastrointest Endosc. 2009 May;69(6):1111-6. doi: 10.1016/j.gie.2008.07.014. Epub 2009 Feb 24.

PMID:
19243765
16.

Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver -- results of a pilot study.

Deibert P, Schumacher YO, Ruecker G, Opitz OG, Blum HE, Rössle M, Kreisel W.

Aliment Pharmacol Ther. 2006 Jan 1;23(1):121-8.

17.

Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects.

Werkström V, Svensson A, Andersson KE, Hedlund P.

BJU Int. 2006 Aug;98(2):414-23. Epub 2006 Apr 18.

18.

The management of phosphodiesterase-5 (PDE5) inhibitor failure.

Lau DH, Kommu S, Mumtaz FH, Morgan RJ, Thompson CS, Mikhailidis DP.

Curr Vasc Pharmacol. 2006 Apr;4(2):89-93. Review.

PMID:
16611151
19.

Long-term effects of thoracic sympathectomy on microcirculation in the hands of patients with primary Raynaud disease.

Maga P, Kuzdzał J, Nizankowski R, Szczeklik A, Sładek K.

J Thorac Cardiovasc Surg. 2007 Jun;133(6):1428-33.

20.

Systemic sclerosis: blood rheometry and laser Doppler imaging of digital cutaneous microcirculation during local cold exposure.

Picart C, Carpentier PH, Brasseur S, Galliard H, Piau JM.

Clin Hemorheol Microcirc. 1998 Apr;18(1):47-58.

PMID:
9653586

Supplemental Content

Support Center